Registry of Lobbyists
Subject matters | Details | Categories |
---|---|---|
Health,
Research and Development
|
Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.
|
Policies or Program,
Regulation
|
Health,
Research and Development
|
Communications regarding access to and approval of medicines addressing the growing public health threat of antimicrobial resistance.
|
Policies or Program
|
Intellectual Property,
International Trade
|
Communications regarding intellectual property protection of prescription drugs, including the Patent Act, the Patented Medicines Regulations, the Patented Medicine Notice of Compliance (PMNOC) Regulations, the Patent Term Adjustment regime and Health Canada’s Data Protection regime.
|
Policies or Program,
Regulation
|
Federal-Provincial Relations,
Health
|
Communications regarding national pharmacare legislation, regulations, policies or programs.
|
Legislative Proposal, Bill or Resolution,
Policies or Program,
Regulation
|
Health
|
Communications regarding the design and implementation of the federal Drugs for Rare Diseases strategy.
|
Policies or Program
|
Health
|
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
|
Policies or Program
|
Health,
Research and Development
|
Communications with Health Canada regarding guidelines for pediatric action plans.
|
Policies or Program
|
Health,
Research and Development
|
Communications with Health Canada regarding modernization of clinical trials regulations, including diversity and inclusivity of clinical trials.
|
Policies or Program,
Regulation
|
Health
|
Communications with Health Canada regarding the application of its nitrosamine guidelines.
|
Policies or Program
|
Health,
Research and Development
|
Communications with Health Canada regarding the evolution of the regulatory framework to address advanced therapeutic products.
|
Policies or Program,
Regulation
|
Health,
Research and Development
|
Communications with Heath Canada regarding modernization of the medical devices regulatory framework.
|
Policies or Program,
Regulation
|
Health,
International Trade
|
Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages.
|
Policies or Program
|
Aboriginal Affairs,
Health
|
Federal Government Non Insured Health Benefits program with respect to reimbursement of a prescription medicine and changes in type of reimbursement
|
Policies or Program
|
Economic Development,
Industry,
Research and Development
|
Innovation, Science and Economic Development (ISED)'s Biomanufacturing and Life Sciences Strategy, pertaining to growth and development of the life sciences industry in Canada.
|
Policies or Program
|
Economic Development,
Health,
Industry,
Intellectual Property
|
Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.
|
Policies or Program
|
Aboriginal Affairs,
Health
|
Public Health Agency of Canada, regarding the federal response to the hepatitis C virus.
|
Policies or Program
|
Health
|
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
|
Policies or Program
|
Subject matters | Details | Categories |
---|---|---|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Acts that propose to amend the Food and Drug Act and amendments to the Food and Drug Regulations related to the regulation of pharmaceuticals, biologic therapies, medical devices and foods.
|
Legislative Proposal, Bill or Resolution,
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Canada's Drug and Health Technology Agency (CADTH) and the pan Canadian Pharmaceutical Alliance (pCPA), with respect to value assessment and public formulary listing of new medicines.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Common Drug Review (CDR), with respect to health economics assessment and recommendations made on new medicines.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.
|
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Communications regarding a national pharmacare program and Canada Drug Agency.
|
Legislative Proposal, Bill or Resolution,
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Communications regarding access to and approval of medicines addressing the growing public health threat of antimicrobial resistance.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Communications regarding intellectual property protection of prescription drugs, including the Patent Act, the Patented Medicines Regulations, the Patented Medicine Notice of Compliance (PMNOC) Regulations, the Patent Term Adjustment regime and Health Canada’s Data Protection regime.
|
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Communications regarding national pharmacare legislation, regulations, policies or programs.
|
Legislative Proposal, Bill or Resolution,
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Communications regarding the design and implementation of the federal Drugs for Rare Diseases strategy.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Communications regarding the value assessment of new medicines by the Canadian Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Communications with Health Canada regarding guidelines for pediatric action plans.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Communications with Health Canada regarding modernization of clinical trials regulations, including diversity and inclusivity of clinical trials.
|
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Communications with Health Canada regarding the application of its nitrosamine guidelines.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Communications with Health Canada regarding the evolution of the regulatory framework to address advanced therapeutic products.
|
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Communications with Heath Canada regarding modernization of the medical devices regulatory framework.
|
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federal Government Non Insured Health Benefits program with respect to reimbursement of a prescription medicine and changes in type of reimbursement
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Implementation of Patented Medicine Notice of Compliance (PMNOC) Regulations and Patent Term Adjustment regime, as this relates to intellectual property protection of prescription drugs.
|
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Innovation, Science and Economic Development (ISED)'s Biomanufacturing and Life Sciences Strategy, pertaining to growth and development of the life sciences industry in Canada.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Innovation, Science and Economic Development Canada (PMNOC) Regulations, as this relates to regulating intellectual property of prescription drugs; as well as discussions pertaining to growth and development of the life sciences industry in Canada, including as part of an Innovation Agenda.
|
Legislative Proposal, Bill or Resolution,
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patented Medicine Prices Review Board (PMPRB) Regulations.
with regard to prices charged by patentees for patented medicines sold in Canada.
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Pharmaceutical intellectual property proposals that are part of the Comprehensive Economic and Trade Agreement with the European Union.
|
Legislative Proposal, Bill or Resolution,
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Public Health Agency of Canada, regarding the federal response to the hepatitis C virus.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Similar Entry Biologics (SEBs): requiring a Health Canada regulatory framework that support the approval of SEBs
|
Legislative Proposal, Bill or Resolution,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
|
Policies or Program
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Date | DPOH, Position Title | Government Institution | Subject Matters |
---|---|---|
2024-09-24 |
|
Health, Industry |
2024-06-13 |
|
Health, Industry |
2024-06-11 |
|
Health |
2024-06-04 |
|
Economic Development, Research and Development |
2024-06-03 |
|
Economic Development, Research and Development |
2024-05-09 |
|
Intellectual Property |
2024-04-15 |
|
Health, Industry |
2024-04-15 |
|
Industry |
2024-04-03 |
|
Industry, Research and Development |
2024-02-12 |
|
Health, Industry |
2023-12-19 |
|
Health, Industry |
2023-11-09 |
|
Health, Industry, Science and Technology |
2023-10-26 |
|
Health, Industry |
2023-10-20 |
|
Health |